Waiariki Institute of Technology, June 26, 2014
Manuka honey may offer new hope in the global search for ways to tackle life-threatening superbugs.
Recent research in New Zealand has shown that a manuka honey–based formulation with CycloPower™ inhibits the growth of MRSA (methicillin-resistant Staphylococcus aureus).
Manuka honey expert Dr Lynne Chepulis, senior lecturer at Rotorua’s Waiariki Institute of Technology’s Faculty of Health, Education and Humanities, says the unique antibacterial activity of manuka honey has been known for many years.
“But what’s really exciting about this work is that combining manuka honey with CycloPower ™ has been shown in the lab to be even more effective in inhibiting the growth of MRSA,” she says.
Manuka Honey with CycloPower™ employs a novel delivery method in which the active antibacterial ingredient in manuka honey, methylglyoxal, is combined with beneficial natural fibre (cyclodextrins) to increase its activity.
Manuka honey with CycloPower ™ is a proprietary product developed by New Zealand biotechnology company Manuka Health, which commissioned the University of Auckland to conduct this research…